Amedisys Reports Fourth Quarter and Year End 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Amedisys (AMED) Tops Q4 EPS by 2c
February 24, 2021 4:07 PM ESTAmedisys (NASDAQ: AMED) reported Q4 EPS of $1.49, $0.02 better than the analyst estimate of $1.47. Revenue for the quarter came in at $550.71 million versus the consensus estimate of $553.37 million.
GUIDANCE:
Amedisys sees FY2021 EPS of $6.25-$6.47, versus the consensus of $6.31.... More
